Instead of waiting until they're ready to sell, founders should consult with M&A brokers years in advance. This allows them to understand the key metrics buyers value (e.g., IP, recurring revenue) and then spend the intervening years deliberately building a business that will command a premium price.

Taking a small amount of money off the table via a secondary sale de-risks a founder's personal finances. This financial security empowers them to reject large acquisition offers and pursue a long-term, independent vision without the pressure of life-changing personal wealth decisions.

Apogee built its strategy around known biological mechanisms, focusing innovation solely on antibody engineering. This allowed them to de-risk assets early and efficiently (e.g., proving half-life in healthy volunteers). This clear, stepwise reduction of risk proved highly attractive to capital markets, enabling them to raise significant funds for late-stage development.

Pat Flynn structured his company, SPI, to be sellable not with the initial intent to sell, but to ensure its survival and his family's security if something happened to him. This operational independence is what ultimately created the option for a successful exit later on.

The path to an exit is a market in itself. It's often easier to sell a $20M company you fully own than a $500M venture-backed one. The pool of buyers is larger and the process less scrutinized, making a smaller, bootstrapped exit potentially more profitable for the founder.

An acquisition should be a potential outcome, not the core strategy. Companies built with the intention of being sold often fail to play out satisfactorily. The most valuable companies are built with the conviction and operational mindset to become fully integrated, standalone entities.

To justify a high acquisition multiple, a founder must prove the business can operate without them. A powerful tactic is showing an acquirer your calendar to demonstrate that a majority of key clients are managed by the team, not the founder. This de-risks the acquisition and proves the company has true enterprise value.

When acquiring a business, don't rely on a single outcome like achieving a growth target. Instead, seek assets that offer multiple ways to win. Even if the primary goal is missed, the acquired data, technology, or talent could create significant value for other business units, providing built-in insurance for the deal.

To achieve a high-value acquisition, biotechs must first build a credible strategy to succeed independently, creating a position of strength. Concurrently, leaders should keep multiple potential suitors proactively informed on all business aspects—not just clinical data—to facilitate a competitive bidding process when the time comes.